EBS Emergent BioSolutions Inc. stock chart & analysis
Conviction 36HealthcareScan · Fri, Nov 6, 2026Emergent BioSolutions Inc. (EBS) closed at $6.06 (+3.59%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 43, RS Rating 72, -57.0% from its 52-week high, -51.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
EBS technical analysis
Trend
EBS is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 7.3% below the 50-day ($6.53) and 23.3% below the 200-day ($7.88). ADX(14) at 18 points to a weak trend — more range than direction. It meets 2 of 8 trend-template criteria.
Momentum
RSI(14) is 43, in the bearish half of its range. MACD crossed below its signal line 3 sessions ago. Its RS Rating of 72 puts its weighted 12-month performance ahead of about 72% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $7.2M a day on average. ATR(14) is $0.4691, 7.8% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.08) shows distribution.
Key levels
The chart pattern's support is $5.76 and its resistance $7.49. The 52-week range is $4.36 to $14.06; price is 57.0% below the high and 38.8% above the low. The VWAP anchored at the 52-week high is $7.80, above price.
Performance
EBS returned -11.2% (1 week), -11.2% (1 month), +35.4% (3 months), -36.3% (6 months), -41.5% (1 year), -51.0% (year to date).
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Pharmaceutical Preparations · Listed 2006 · 900 employees
Recent news
- Emergent BioSolutions Inc.: Material event (8-K)SEC EDGAR · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in EBS · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Steve Cohen house · D · TN · traded 2024-12-11 | Sell | $1K–$15K | 2024-12-11 | 2025-01-10 |
Insider activity
SEC Form 4 transactions in EBS · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
DeGolyer Donald W Director · Common Stock · 2026-10-07 | Sell | 17.8K | $126K | 2026-10-07 | 2026-10-07 |
Williams Paul Anthony SVP, Products Business · Common Stock · 2026-10-01 | Sell | 3K | $20K | 2026-10-01 | 2026-10-05 |
Hartzel William SVP, Bioservices · Common Stock · 2026-06-08 | Tax | 1.74K | $14K | 2026-06-08 | 2026-06-10 |
Glessner Coleen EVP, Quality & Ethics, and CPL · Common Stock · 2026-06-08 | Tax | 2.02K | $16K | 2026-06-08 | 2026-06-10 |
Williams Paul Anthony SVP, Products Business · Common Stock · 2026-06-08 | Tax | 694 | $6K | 2026-06-08 | 2026-06-10 |
LINDAHL RICHARD S EVP, Chief Financial Officer · Common Stock · 2026-06-08 | Tax | 3.96K | $32K | 2026-06-08 | 2026-06-10 |
Dayal Sujata Tyagi Director · Common Stock · 2026-05-01 | Sell | 980 | $9K | 2026-05-01 | 2026-05-04 |
Dayal Sujata Tyagi Director · Common Stock · 2026-05-01 | Sell | 12.78K | $107K | 2026-05-01 | 2026-05-04 |
Zoon Kathryn C Director · Common Stock · 2026-05-01 | Sell | 1.06K | $9K | 2026-05-01 | 2026-05-04 |
DeGolyer Donald W Director · Common Stock · 2026-05-01 | Sell | 954 | $9K | 2026-05-01 | 2026-05-04 |
SEC filings
EDGAR filings in EBS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.